Kit containing stem cells and cytokines for use in attenuating immune responses

Abstract

The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).

What is claimed is: 
     
       1. A kit for attenuating an immune response mediated by activated T-cells in a subject in need thereof comprising
 (a) a pharmaceutically acceptable carrier selected from the group consisting of phosphate-buffered saline, physiological saline, 5% aqueous dextrose, and a mixture thereof; 
 (b) a population of stem cells as the sole cell source within the kit consisting of cloned mesenchymal stem cells; 
 (c) isolated interferon gamma; 
 (d) isolated interleukin-1 alpha, interleukin-1 beta or tumor necrosis factor alpha; and 
 (e) instructions for using the kit so that an immune response mediated by activated T-cells is attenuated. 
 
     
     
       2. The kit of  claim 1 , whereby the administration of a combination of (a), (b), (c) and (d) to a subject in need thereof achieves immunosuppression. 
     
     
       3. The kit of  claim 1 , wherein the instruction provides for administration of (a), (b), (c) and (d) to a subject in need thereof for achieving immunosuppression. 
     
     
       4. A kit for attenuating an immune response mediated by activated T-cells in a subject in need thereof comprising
 (a) a pharmaceutically acceptable carrier selected from the group of phosphate-buffered saline, physiological saline, 5% aqueous dextrose and a mixture thereof; 
 (b) a population of stem cells as the sole cell source within the kit consisting of cloned mesenchymal stem cells; 
 (c) isolated interferon gamma; 
 (d) isolated interleukin-1 alpha, or interleukin-1 beta; and 
 (e) instructions for using the kit so that an immune response mediated by activated T-cells is attenuated. 
 
     
     
       5. The kit of  claim 4 , wherein the instruction provides for administration of (a), (b), (c) and (d) to a subject in need thereof for achieving immunosuppression.